Expert Interview
Examining the Market Potential for JAKs treating moderate-to-severe alopecia areata
Ticker(s): CNCE, LLY, PFE, INCYA clinician with extensive experience treating patients with alopecia areata.
On a scale of 1-10, 10 being super excited, where would you put CTP-543?
Added By: joe_mccannHow concerned are you with balancing the potential of adverse events with the efficacy that you've seen from JAK in the patients both in the published literature?
Added By: joe_mccannDo you think a topical JAK would work as well?
Added By: joe_mccannRegarding the relationship between alopecia areata and vitiligo, what similarities exist among the conditions treatment-wise?
Added By: joe_mccannIs the small number of JAK-patients due to reimbursement reasons or the steroids and the first-line treatment options being somewhat ineffective? If it were covered by insurance, would JAK change its role in your treatment paradigm?
Added By: joe_mccannHow do you currently go about treating patients with alopecia areata, in terms of first-line and second-line treatment?
Added By: joe_mccannPlease describe your clinical practice. How many patients alopecia areata do you currently treat?
Added By: joe_mccannWhat has your experience been using JAK inhibitors, and how many patients have you treated with this method?
Added By: joe_mccannAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
